Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon (BME: ORY) further extends US patent portfolio
Published by Arron Aatkar, PhD

Oryzon Genomics has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent “Methods of treating borderline personality disorder”, specifically covering the use of vafidemstat for the treatment of non-aggressive symptoms of BPD, complementing the company’s patent portfolio in aggression.

Once formally granted, this should provide protection to at least 2040, excluding any other potential patent term extensions. Corresponding patents have been granted or allowed in Australia, Europe, Japan, Mexico, Russia, Singapore and South Africa, with additional applications pending in other key regions.

For more detail on Oryzon’s ongoing activities, please see our recently published outlook note.